Biosortia Microbiomics, founded with the mission to revolutionize drug discovery, focuses on unlocking the vast untapped potential of microbiomes. The company aims to modernize and improve traditional methodologies, accessing the 99% of microbiomes previously unexplored. Their core services include industrial-scale microbiome mining and small molecule amplification, targeting pharmaceutical and biotech markets to discover novel therapeutics.
Notable figures associated with Biosortia include key advisors and a leadership team with extensive industry experience. The company has achieved significant milestones in advancing drug discovery technologies and forming key industry partnerships. Biosortia's impact lies in its innovative approach to exploring microbiomes, potentially leading to groundbreaking treatments and contributing to the advancement of medical science.
